Predicting ILD from Hypersensitivity Pneumonitis

Trial Objective

Predicting ILD from Hypersensitivity PneumonitisResearchers believe they will be able to predict which patients with chronic Hypersensitivity Pneumonitis (HP) will develop interstitial lung disease (ILD) by looking at their genes and biomarkers in their blood. For this observational study, researchers will collect samples and data from participants with rapidly progressing HP and slowly progressing HP to look for patterns that can help predict the development of ILD and form specialized treatment plans.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have been diagnosed with Hypersensitivity Pneumonitis (HP).

Age: 18-90    Gender: Any Gender


Estimated Time Commitment

Clinic visits every 6 months over approximately 2 years (4 visits total)



Payment & Reimbursement  

Payment: Not Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Melissa Schwab

Melissa Schwab
303.398.1220

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Investigator Initiated with funding from Boehringer Ingelheim

Principal Investigators

Co-Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*